Elamipretide heart failure research is still investigational. Learn what trials show, why the FDA has not approved it, cost, safety, and what comes next.
Elamipretide is an investigational, mitochondria-targeted peptide that researchers have tested in people with heart failure and in patients recovering from a large heart attack. Elamipretide is not FDA-approved for heart failure or for any other condition, and the clinical evidence for a meaningful benefit remains preliminary. If you are searching for an elamipretide heart failure treatment today, what exists is research — not a standard therapy.
What Is Elamipretide?
Elamipretide is a synthetic tetrapeptide, meaning a short chain of four amino acids, engineered to concentrate inside mitochondria, the structures that supply energy to cells. The elamipretide structure (D-Arg-Dmt-Lys-Phe-NH2) pairs a positively charged arginine with a dimethyltyrosine that behaves as an antioxidant, which helps the molecule accumulate on the inner mitochondrial membrane.
The drug's main proposed mechanism is binding to cardiolipin, a phospholipid that anchors the electron transport chain. Damaged cardiolipin is linked to electron leakage, excess reactive oxygen species, and lower ATP output, so stabilizing it is thought to improve mitochondrial efficiency.
Current elamipretide uses in research include Barth syndrome, primary mitochondrial myopathy, dry age-related macular degeneration, and cardiac conditions such as acute myocardial infarction and heart failure with reduced ejection fraction. None of those programs has produced an FDA-approved product so far.
Why Mitochondria Matter in Heart Failure
Heart muscle burns more ATP per gram than nearly any other tissue, and it never gets to rest. When mitochondrial function declines, the heart loses the energy it needs to contract and relax efficiently.
In failing hearts, researchers consistently observe:
- Lower ATP production and reduced mitochondrial density
- Increased oxidative stress that damages cardiolipin and mitochondrial DNA
- Impaired calcium handling and a gradual shift toward fibrosis
That biology makes mitochondria an attractive drug target. A reasonable mechanism, however, does not guarantee that a drug improves symptoms, hospitalizations, or survival.
What Elamipretide Heart Failure Research Has Found
Most cardiovascular data come from an elamipretide clinical trial called EMBRACE-STEMI, a Phase 2 study in patients who had a large anterior heart attack with reduced left ventricular function. The study was designed primarily to assess safety and tolerability, and the sponsor reported fewer heart failure events over one year among treated patients. The trial was far too small to prove that elamipretide prevents heart failure or saves lives.
| Trial | Population | Reported result | Status |
|---|---|---|---|
| EMBRACE-STEMI (Phase 2) | Anterior STEMI with left ventricular dysfunction | Signals of fewer heart failure events at one year; not powered for outcomes | Completed; no large outcomes trial reported |
| TAZPOWER (Phase 2/3) | Barth syndrome | Mixed results; some functional measures improved, primary endpoints not clearly met | Received a complete response letter from the FDA |
| MMPOWER-3 (Phase 3) | Primary mitochondrial myopathy | Did not meet its primary endpoint | Completed |
| ReCLAIM and ReCLAIM-2 | Dry age-related macular degeneration | Some visual function improvements reported | Investigational |
That mixed track record matters. Peptides that look promising in small studies frequently fail when they are tested in thousands of patients.
Barth syndrome: the closest thing to a proof of concept
In elamipretide barth syndrome research, the drug is given as a daily subcutaneous injection to boys with the rare X-linked disorder, which impairs cardiolipin metabolism and can cause cardiomyopathy. Reports described gains in walking distance and some heart-related measures, but regulators concluded the evidence was not sufficient. In early 2025 the FDA declined to approve elamipretide for Barth syndrome and asked for additional data.
Is Elamipretide Approved for Heart Failure?
No. Elamipretide has no FDA approval for heart failure, and there is no prescription version available in the United States. The FDA's 2025 decision on Barth syndrome was a complete response letter, meaning the agency found the application insufficient rather than approvable.
That status has practical consequences. Outside of a clinical trial, a physician cannot prescribe elamipretide for heart failure, and any product sold online under that name should be treated as unverified at best.
Elamipretide Cost and What Access Looks Like
Because the drug is investigational, there is no published elamipretide cost and no insurance billing code. Participants in trials typically receive the drug and study visits at no charge, though travel, time off work, and follow-up appointments are real costs.
If approval ever comes, expect specialty pricing. Mitochondria-targeted peptides are injectable products that require cold-chain handling, and orphan-drug launches in the US often exceed six figures per year before insurers negotiate rebates.
Safety, Side Effects, and Realistic Expectations
In published trials, elamipretide has generally been tolerated. Injection-site reactions such as redness, pain, and swelling were reported most often, with headache and mild gastrointestinal upset also described.
Short-term safety in a few hundred patients does not establish long-term safety, especially for a drug intended to be injected daily for years. Anyone considering elamipretide for heart failure should talk with a cardiologist and explore trial participation instead of unregulated sources.
Key Takeaways
- Elamipretide is an investigational mitochondria-targeted peptide with a plausible but unproven mechanism in heart failure.
- Heart failure evidence comes from a small Phase 2 trial; no large study has shown reduced mortality or hospitalizations.
- No regulatory agency has approved elamipretide for heart failure or any other indication.
- Enrollment in a registered clinical trial is the only legitimate route to the drug today.
ClinicalTrials.gov lists open studies by condition and location, and a cardiologist can help you judge whether a trial is a reasonable option. For now, guideline-directed heart failure therapy remains the proven path, and elamipretide stays a question for research rather than a prescription.
Frequently Asked Questions
Is elamipretide approved for heart failure?
No. Elamipretide is not FDA-approved for heart failure or for any other condition in the United States. The only cardiovascular data come from a small Phase 2 trial, and the FDA declined to approve the drug for Barth syndrome in 2025.
What is elamipretide used for?
Elamipretide has been studied for Barth syndrome, primary mitochondrial myopathy, dry age-related macular degeneration, and heart conditions including heart attack with left ventricular dysfunction. All of these remain investigational uses rather than approved indications. It is given as an injection in clinical research settings.
How much does elamipretide cost?
There is no public price because elamipretide is not commercially available. Trial participants usually receive the drug at no cost, though travel and time commitments add up. If it were ever approved, specialty injectable pricing would likely be very high before insurance negotiation.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.